Does Aspirin Reduce Vascepa's Heart Benefits?
Vascepa (icosapent ethyl) lowers cardiovascular events like heart attacks and strokes in high-risk patients with elevated triglycerides, as shown in the REDUCE-IT trial.[1] Aspirin, used for its antiplatelet effects to prevent clots, can interact with Vascepa's benefits. A 2023 subanalysis of REDUCE-IT found that patients on aspirin (≤325 mg/day) experienced similar absolute risk reductions from Vascepa as those not on aspirin—about 4.8% vs. 4.7% over five years for the primary composite endpoint (CV death, MI, stroke, revascularization).[2] However, the relative risk reduction was lower in aspirin users (18% vs. 31%), likely due to aspirin's baseline risk-lowering effect making further gains harder to detect statistically.
How Was This Interaction Studied?
REDUCE-IT randomized 8,179 statin-treated patients with triglycerides 135-499 mg/dL and other CV risk factors to Vascepa 4g/day or placebo. Aspirin use was common (about 45% at baseline), and the trial allowed concurrent antiplatelets.[1][2] No adjustment for aspirin was prespecified in the main analysis, but the post-hoc subanalysis stratified by aspirin exposure confirmed consistent benefits across groups (interaction p=0.38, not significant).[2] This suggests aspirin doesn't negate Vascepa's effects but may blunt relative gains.
What About Higher-Dose Aspirin or Bleeding Risks?
High-dose aspirin (>325 mg/day) wasn't common in REDUCE-IT, and data is limited. Vascepa alone increases bleeding risk slightly (2.7% serious bleeds vs. 2.1% placebo), which could compound with aspirin's effects.[1] The subanalysis excluded high-dose users, so caution applies for those on >325 mg aspirin. Guidelines recommend monitoring in dual therapy.[3]
Should Patients on Aspirin Stop or Adjust Vascepa?
No—REDUCE-IT supports Vascepa's use with low-to-moderate dose aspirin for eligible patients.[2][4] FDA labeling doesn't contraindicate this combo.[5] Consult a doctor for individual risks, especially with history of bleeding or high-dose aspirin.
How Does This Compare to Other Omega-3s or Statins?
Unlike mixed omega-3s (e.g., Lovaza), which failed CV outcomes in trials like STRENGTH, Vascepa's pure EPA form drove benefits independent of aspirin.[6] With statins (mandatory in REDUCE-IT), no negative interaction occurred.[1]
Sources
[1]: NEJM - REDUCE-IT Trial
[2]: JACC - REDUCE-IT Aspirin Subanalysis
[3]: AHA/ACC Lipid Guidelines
[4]: FDA Vascepa Label
[5]: Drugs.com - Vascepa Interactions
[6]: NEJM - STRENGTH Trial